Free Trial
NASDAQ:JYNT

Joint (JYNT) Stock Price, News & Analysis

Joint logo
$9.24 +0.02 (+0.22%)
Closing price 06/16/2026 04:00 PM Eastern
Extended Trading
$9.89 +0.65 (+7.01%)
As of 06:22 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

About Joint Stock (NASDAQ:JYNT)

Advanced

Key Stats

Today's Range
$9.08
$9.34
50-Day Range
$8.20
$9.58
52-Week Range
$7.50
$13.00
Volume
39,318 shs
Average Volume
88,355 shs
Market Capitalization
$131.72 million
P/E Ratio
40.17
Dividend Yield
N/A
Price Target
$18.00
Consensus Rating
Moderate Buy

Company Overview

Joint Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
91st Percentile Overall Score

JYNT MarketRank™: 

Joint scored higher than 91% of companies evaluated by MarketBeat, and ranked 53rd out of 855 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Joint has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on 1 strong buy rating, no buy ratings, 2 hold ratings, and no sell ratings.

  • Upside Potential

    Joint has a consensus price target of $18.00, representing about 94.8% upside from its current price of $9.24.

  • Amount of Analyst Coverage

    Joint has only been the subject of 2 research reports in the past 90 days.

  • Read more about Joint's stock forecast and price target.
  • Earnings Growth

    Earnings for Joint are expected to grow by 23.53% in the coming year, from $0.51 to $0.63 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Joint is 40.17, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 44.54.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Joint is 40.17, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 23.88.

  • Price to Book Value per Share Ratio

    Joint has a P/B Ratio of 9.15. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about Joint's valuation and earnings.
  • Percentage of Shares Shorted

    7.54% of the float of Joint has been sold short.
  • Short Interest Ratio / Days to Cover

    Joint has a short interest ratio ("days to cover") of 9.54.
  • Change versus previous month

    Short interest in Joint has recently decreased by 5.42%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Joint does not currently pay a dividend.

  • Dividend Growth

    Joint does not have a long track record of dividend growth.

  • News Sentiment

    Joint has a news sentiment score of 0.94. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 1 news article for Joint this week, compared to 2 articles on an average week.
  • Net Insider Buying

    Over the last three months, insiders have purchased a net $1,098,551.00 in company stock, which represents 0.8340% of the company's market cap.

  • Insider Buying vs. Insider Selling

    In the past three months, Joint insiders have bought more of their company's stock than they have sold. Specifically, they have bought $1,098,551.00 in company stock and sold $0.00 in company stock.

  • Percentage Held by Insiders

    30.20% of the stock of Joint is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    76.88% of the stock of Joint is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Joint's insider trading history.
Receive JYNT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Joint and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

JYNT Stock News Headlines

Joint (NASDAQ:JYNT) Rating Lowered to "Buy" at Wall Street Zen
Iran War Shock: What I Was Told In That Private Meeting
You’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially the reasons why we’re bombing the country.tc pixel
The Joint (JYNT) Q1 2026 Earnings Transcript
See More Headlines

JYNT Stock Analysis - Frequently Asked Questions

Joint's stock was trading at $8.72 on January 1st, 2026. Since then, JYNT shares have increased by 6.0% and is now trading at $9.24.

The Joint Corp. (NASDAQ:JYNT) released its quarterly earnings results on Thursday, May, 7th. The company reported $0.08 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.03 by $0.05. The company earned $14.82 million during the quarter, compared to analysts' expectations of $14.50 million. Joint had a trailing twelve-month return on equity of 7.00% and a net margin of 5.72%.
Read the conference call transcript
.

Joint's board initiated a stock repurchase program on Thursday, June 5th 2025, which permits the company to buy back $5,000,000 in outstanding shares, according to EventVestor. This means that the company could buy up to 2.7% of its stock through open market purchases. Stock repurchase programs are typically an indication that the company's management believes its shares are undervalued.

Joint (JYNT) raised $20 million in an initial public offering (IPO) on Tuesday, November 11th 2014. The company issued 3,000,000 shares at a price of $6.00-$7.00 per share. Roth Capital Partners and Feltl and Company served as the underwriters for the IPO and Sanders Morris Harris was co-manager.

Joint's top institutional investors include Skylands Capital LLC (6.24%), Renaissance Technologies LLC (1.60%), Dimensional Fund Advisors LP (1.07%) and Verus Capital Partners LLC (0.92%). Insiders that own company stock include Bandera Partners Llc and Christopher M Grandpre.
View institutional ownership trends
.

Shares of JYNT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Joint investors own include American Water Works (AWK), Humana (HUM), Waste Connections (WCN), Voyager Therapeutics (VYGR), The RMR Group (RMR), AUO (AUOTY) and DiamondRock Hospitality (DRH).

Company Calendar

Last Earnings
5/07/2026
Today
6/17/2026
Next Earnings (Estimated)
8/06/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - HMO
Sub-Industry
Trading
Current Symbol
NASDAQ:JYNT
CIK
1612630
Employees
320
Year Founded
1999

Price Target and Rating

High Price Target
$18.00
Low Price Target
$18.00
Potential Upside/Downside
+94.8%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.67
Research Coverage
3 Analysts

Profitability

EPS (Trailing Twelve Months)
$0.23
Trailing P/E Ratio
40.17
Forward P/E Ratio
18.12
P/E Growth
N/A
Net Income
$2.91 million
Net Margins
5.72%
Pretax Margin
2.43%
Return on Equity
7.00%
Return on Assets
2.05%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
1.64
Quick Ratio
1.64

Sales & Book Value

Annual Sales
$56.64 million
Price / Sales
2.33
Cash Flow
$0.10 per share
Price / Cash Flow
94.79
Book Value
$1.01 per share
Price / Book
9.15

Miscellaneous

Outstanding Shares
14,255,000
Free Float
9,950,000
Market Cap
$131.72 million
Optionable
Optionable
Beta
1.12

Social Links

10 Stocks Set to Soar in 2026 Cover

Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Summer 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

This page (NASDAQ:JYNT) was last updated on 6/17/2026 by MarketBeat.com Staff.
From Our Partners